Loading...

BioGaia

DB:BGL
Snowflake Description

Flawless balance sheet with outstanding track record and pays a dividend.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BGL
DB
SEK8B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

BioGaia AB (publ) develops, markets, and sells probiotic products with documented health benefits worldwide. The last earnings update was 29 days ago. More info.


Add to Portfolio Compare Print
BGL Share Price and Events
7 Day Returns
-1.3%
DB:BGL
-2.7%
DE Biotechs
1.5%
DE Market
1 Year Returns
-2.3%
DB:BGL
-10.6%
DE Biotechs
-6.2%
DE Market
BGL Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
BioGaia (BGL) -1.3% -1.9% 22.9% -2.3% 95.3% 106.2%
DE Biotechs -2.7% 3.8% -8.5% -10.6% 47.4% 10.3%
DE Market 1.5% 6% 8.5% -6.2% 10.7% 15.3%
1 Year Return vs Industry and Market
  • BGL outperformed the Biotechs industry which returned -10.6% over the past year.
  • BGL outperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
BGL
Industry
5yr Volatility vs Market

BGL Value

 Is BioGaia undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of BioGaia to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for BioGaia.

DB:BGL Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 3 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:BGL
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.449 (1 + (1- 22%) (0%))
1.301
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.3
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.301 * 5.96%)
7.98%

Discounted Cash Flow Calculation for DB:BGL using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for BioGaia is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:BGL DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (SEK, Millions) Source Present Value
Discounted (@ 7.98%)
2019 201.67 Analyst x3 186.76
2020 232.33 Analyst x3 199.26
2021 275.00 Analyst x3 218.42
2022 306.89 Est @ 11.6% 225.73
2023 332.01 Est @ 8.19% 226.16
2024 351.26 Est @ 5.8% 221.59
2025 365.75 Est @ 4.13% 213.68
2026 376.57 Est @ 2.96% 203.74
2027 384.62 Est @ 2.14% 192.71
2028 390.64 Est @ 1.57% 181.26
Present value of next 10 years cash flows SEK2,069.30
DB:BGL DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= SEK390.64 × (1 + 0.23%) ÷ (7.98% – 0.23%)
SEK5,050.11
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= SEK5,050.11 ÷ (1 + 7.98%)10
SEK2,343.30
DB:BGL Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= SEK2,069.30 + SEK2,343.30
SEK4,412.60
Equity Value per Share
(SEK)
= Total value / Shares Outstanding
= SEK4,412.60 / 17.34
SEK254.53
DB:BGL Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:BGL represents 0.09208x of OM:BIOG B
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.09208x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (SEK) x Listing Adjustment Factor
= SEK 254.53 x 0.09208
€23.44
Value per share (EUR) From above. €23.44
Current discount Discount to share price of €42.45
= -1 x (€42.45 - €23.44) / €23.44
-81.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of BioGaia is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for BioGaia's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are BioGaia's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:BGL PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in SEK SEK12.40
OM:BIOG B Share Price ** OM (2019-04-23) in SEK SEK461
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.6x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of BioGaia.

DB:BGL PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OM:BIOG B Share Price ÷ EPS (both in SEK)

= 461 ÷ 12.40

37.19x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BioGaia is overvalued based on earnings compared to the Europe Biotechs industry average.
  • BioGaia is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does BioGaia's expected growth come at a high price?
Raw Data
DB:BGL PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 37.19x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
13.1%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

DB:BGL PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 37.19x ÷ 13.1%

2.84x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BioGaia is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on BioGaia's assets?
Raw Data
DB:BGL PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in SEK SEK29.13
OM:BIOG B Share Price * OM (2019-04-23) in SEK SEK461
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:BGL PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OM:BIOG B Share Price ÷ Book Value per Share (both in SEK)

= 461 ÷ 29.13

15.83x

* Primary Listing of BioGaia.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BioGaia is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess BioGaia's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. BioGaia has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

BGL Future Performance

 How is BioGaia expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is BioGaia expected to grow at an attractive rate?
  • BioGaia's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • BioGaia's earnings growth is expected to exceed the Germany market average.
  • BioGaia's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:BGL Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:BGL Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 13.1%
DB:BGL Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 14.8%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:BGL Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in SEK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:BGL Future Estimates Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31 1,438 1
2021-12-31 1,113 303 307 3
2020-12-31 953 257 258 3
2019-12-31 815 223 210 3
DB:BGL Past Financials Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income *
2018-12-31 742 183 215
2018-09-30 702 223 206
2018-06-30 675 192 197
2018-03-31 631 181 181
2017-12-31 615 223 181
2017-09-30 584 201 179
2017-06-30 562 210 172
2017-03-31 542 198 163
2016-12-31 535 148 160
2016-09-30 500 115 138
2016-06-30 480 86 129
2016-03-31 478 108 130

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • BioGaia's earnings are expected to grow by 13.1% yearly, however this is not considered high growth (20% yearly).
  • BioGaia's revenue is expected to grow by 14.8% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:BGL Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from BioGaia Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:BGL Future Estimates Data
Date (Data in SEK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31
2021-12-31 17.71 22.24 14.00 3.00
2020-12-31 14.94 17.72 12.20 3.00
2019-12-31 12.06 12.58 11.20 3.00
DB:BGL Past Financials Data
Date (Data in SEK Millions) EPS *
2018-12-31 12.40
2018-09-30 11.89
2018-06-30 11.36
2018-03-31 10.43
2017-12-31 10.42
2017-09-30 10.34
2017-06-30 9.93
2017-03-31 9.43
2016-12-31 9.21
2016-09-30 7.95
2016-06-30 7.42
2016-03-31 7.48

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • BioGaia is expected to make outstanding use of shareholders’ funds in the future (Return on Equity greater than 40%).
X
Future performance checks
We assess BioGaia's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
BioGaia has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

BGL Past Performance

  How has BioGaia performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare BioGaia's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • BioGaia's year on year earnings growth rate has been positive over the past 5 years.
  • BioGaia's 1-year earnings growth exceeds its 5-year average (19% vs 12.9%)
  • BioGaia's earnings growth has exceeded the Europe Biotechs industry average in the past year (19% vs 18.2%).
Earnings and Revenue History
BioGaia's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from BioGaia Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:BGL Past Revenue, Cash Flow and Net Income Data
Date (Data in SEK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 741.87 214.89 180.76 99.74
2018-09-30 702.35 206.19 173.30 93.66
2018-06-30 675.35 196.89 166.08 85.99
2018-03-31 630.52 180.83 153.34 78.29
2017-12-31 615.00 180.56 149.18 75.70
2017-09-30 583.61 179.19 142.53 70.08
2017-06-30 561.98 172.10 138.72 68.98
2017-03-31 541.98 163.49 131.97 66.99
2016-12-31 534.70 159.63 129.00 63.80
2016-09-30 500.34 137.96 118.44 57.26
2016-06-30 480.27 128.62 114.02 53.24
2016-03-31 478.25 129.61 111.22 51.61
2015-12-31 483.24 137.50 112.21 53.28
2015-09-30 500.22 130.09 115.21 59.50
2015-06-30 473.67 118.91 114.34 58.81
2015-03-31 432.03 97.12 114.53 57.63
2014-12-31 481.80 147.41 107.43 53.87
2014-09-30 450.65 145.82 102.46 45.76
2014-06-30 433.38 144.70 98.10 43.08
2014-03-31 426.35 142.22 93.49 41.86
2013-12-31 315.88 61.72 93.75 40.56
2013-09-30 298.06 60.28 92.40 41.42
2013-06-30 298.70 60.70 92.70 39.38
2013-03-31 289.10 60.87 92.80 37.59
2012-12-31 645.25 326.97 90.78 35.79
2012-09-30 655.25 332.53 88.08 35.10
2012-06-30 665.54 333.53 85.93 35.64

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • BioGaia made outstanding use of shareholders’ funds last year (Return on Equity greater than 40%).
  • BioGaia used its assets more efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • BioGaia has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess BioGaia's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
BioGaia has a total score of 6/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

BGL Health

 How is BioGaia's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up BioGaia's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • BioGaia is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • BioGaia's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of BioGaia's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • BioGaia has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from BioGaia Company Filings, last reported 3 months ago.

DB:BGL Past Debt and Equity Data
Date (Data in SEK Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 508.12 0.00 289.79
2018-09-30 451.08 0.00 257.49
2018-06-30 427.50 0.00 215.48
2018-03-31 506.41 0.00 347.87
2017-12-31 463.89 0.00 310.86
2017-09-30 418.22 0.00 240.15
2017-06-30 375.66 0.00 202.58
2017-03-31 457.98 0.00 320.62
2016-12-31 415.18 0.00 243.08
2016-09-30 369.43 0.00 201.55
2016-06-30 333.58 0.00 148.21
2016-03-31 380.03 0.00 221.49
2015-12-31 395.83 0.00 226.90
2015-09-30 374.23 0.00 219.80
2015-06-30 353.12 0.00 202.75
2015-03-31 388.50 0.00 249.95
2014-12-31 344.59 0.00 210.68
2014-09-30 325.58 0.00 224.13
2014-06-30 311.05 0.00 239.12
2014-03-31 413.99 0.00 342.69
2013-12-31 316.86 0.00 234.35
2013-09-30 301.26 0.00 243.19
2013-06-30 318.06 0.00 249.56
2013-03-31 473.89 0.00 397.62
2012-12-31 456.79 0.00 375.05
2012-09-30 441.70 0.00 404.07
2012-06-30 427.97 0.00 414.50
  • BioGaia has no debt.
  • BioGaia has not taken on any debt in the past 5 years.
  • BioGaia has no debt, it does not need to be covered by operating cash flow.
  • BioGaia has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess BioGaia's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. BioGaia has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

BGL Dividends

 What is BioGaia's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
2.17%
Current annual income from BioGaia dividends. Estimated to be 2.34% next year.
If you bought €2,000 of BioGaia shares you are expected to receive €43 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • BioGaia's pays a higher dividend yield than the bottom 25% of dividend payers in Germany (1.43%).
  • BioGaia's dividend is below the markets top 25% of dividend payers in Germany (3.71%).
Upcoming dividend payment

Purchase BioGaia before the 'Buy Limit' to receive their next dividend payment.

Dividends are usually paid every 3 or 6 months, you can time your share purchase to take advantage of upcoming dividend payments.
Dividend payment calendar
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:BGL Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:BGL Future Dividends Estimate Data
Date (Data in SEK) Dividend per Share (annual) Avg. No. Analysts
2022-12-31 11.00 1.00
2021-12-31 11.73 3.00
2020-12-31 10.73 3.00
2019-12-31 9.83 3.00
DB:BGL Past Annualized Dividends Data
Date (Data in SEK) Dividend per share (annual) Avg. Yield (%)
2019-04-05 10.000 2.163
2018-03-26 9.000 2.231
2017-04-06 7.500 2.329
2017-02-10 7.500 2.315
2016-04-14 5.000 1.961
2016-02-12 5.000 2.328
2015-04-08 5.000 1.887
2014-05-08 7.000 3.765
2013-04-29 10.000 4.458
2012-05-08 6.000 3.373
2012-03-21 4.000 1.962
2011-05-11 2.000 1.254
2010-05-07 0.900 0.959
2009-04-24 0.400 0.525

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
  • Dividends per share have increased over the past 10 years.
Current Payout to shareholders
What portion of BioGaia's earnings are paid to the shareholders as a dividend.
  • Dividends paid are well covered by earnings (3.1x coverage).
Future Payout to shareholders
  • Dividends after 3 years are expected to be covered by earnings (1.5x coverage).
X
Income/ dividend checks
We assess BioGaia's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can BioGaia afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. BioGaia has a total score of 4/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

BGL Management

 What is the CEO of BioGaia's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Isabelle Valerie Ducellier
AGE 49
CEO Bio

Ms. Isabelle Valerie Ghislaine Ducellier serves as the Chief Executive Officer of BioGaia AB. Ms. Ducellier has been Partner and Consultant at Anian Ab since 2016. Ms. Ducellier has been Visiting Lecturer at INSEEC since 2015. She was a Director of BioGaia AB from April 25, 2018 to November 2018. She served as Chief Executive Officer of Pernod Ricard Sweden from 2008 to 2016. She served as Regional Sales Director of Pernod Ricard from 2004 to 2008. She served as International Marketing Director of Pernod Ricard Poland – Wyborowa SA from 2002 to 2004. She served as Sales and Marketing Director at Pernod Ricard Sweden from 1997 to 2001. She was an Export Area Manager of Pernod Ricard Group from 1993 to 1997. She served as Product Manager of Pernod Ricard Group from 1992 to 1993 and also served as its Area Sales Manager from 1991 to 1992. She has been Chairman of the Swedish section, Comité National des Conseillers du Commerce Extérieur de la France since 2013. She has been Director of Arcus AS since 2016. She has been Advisory Board Member I at Executive Search AB since 2011. She served as a Director of Arcus ASA from August 24, 2016 to December 2016. She served as a Director of Björn Borg AB (publ) from April 17, 2013 to May 19, 2016. Ms. Ducellier earned Master in International Marketing from EM Lyon from 1989 to 1991 and Executive MBA in Leadership & Innovation from INSEAD in 2010. She completed MBA General Management Program at Harvard Business School from 2015 to 2016.

CEO Compensation
  • Insufficient data for Isabelle Valerie to compare compensation growth.
  • Insufficient data for Isabelle Valerie to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the BioGaia management team in years:

5.1
Average Tenure
50.5
Average Age
  • The average tenure for the BioGaia management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Peter Rothschild

TITLE
Founder & Chairman
COMPENSATION
SEK2M
AGE
68
TENURE
29.3 yrs

Isabelle Valerie Ducellier

TITLE
Chief Executive Officer
AGE
49

Margareta Hagman

TITLE
Executive VP of Accounting
AGE
52
TENURE
9 yrs

Katayoun Welin-Berger

TITLE
Vice President of Operations
AGE
50

Marika Isberg

TITLE
VP & General Counsel
AGE
45
TENURE
1.2 yrs

Urban Strindlöv

TITLE
Executive VP & VP of Sales
AGE
54
TENURE
9.3 yrs

Staffan Strömberg

TITLE
Vice President of Development & Regulatory Affairs
AGE
51

Ulrika Köhler

TITLE
Vice President of Marketing & Product Development
AGE
52

Sebastian Schröder

TITLE
Executive Vice President of Business Development
AGE
45
TENURE
0.4 yrs

Peter Persson

TITLE
Managing Director of BioGaia Production AB
AGE
49
TENURE
0.3 yrs
Board of Directors Tenure

Average tenure and age of the BioGaia board of directors in years:

3.9
Average Tenure
68
Average Age
  • The tenure for the BioGaia board of directors is about average.
Board of Directors

David E. Dangoor

TITLE
Deputy Chairman
COMPENSATION
SEK400K
AGE
69
TENURE
1 yrs

Peter Rothschild

TITLE
Founder & Chairman
COMPENSATION
SEK2M
AGE
68
TENURE
1 yrs

Inger Holmström

TITLE
Director
COMPENSATION
SEK200K
AGE
70
TENURE
12.3 yrs

Brit Stakston

TITLE
Director
COMPENSATION
SEK200K
AGE
57
TENURE
5.3 yrs

Anthon Jahreskog

TITLE
Director
COMPENSATION
SEK200K
AGE
38
TENURE
3.9 yrs

Ewa Björling

TITLE
Director
COMPENSATION
SEK200K
AGE
57
TENURE
3.9 yrs

Peter Elving

TITLE
Director
AGE
70
TENURE
1 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by BioGaia insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
21. Mar 19 Buy Kristina Borg Individual 19. Mar 19 19. Mar 19 40 €44.94 €1,798
01. Mar 19 Buy Peter Rothschild Individual 01. Mar 19 01. Mar 19 200 €41.07 €8,214
26. Nov 18 Sell Annwall & Rothschild Investments AB Company 23. Nov 18 23. Nov 18 -92,404 €33.39 €-3,085,112
19. Nov 18 Sell Peter Rothschild Individual 16. Nov 18 16. Nov 18 -4,700 €34.60 €-162,600
X
Management checks
We assess BioGaia's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. BioGaia has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

BGL News

Simply Wall St News

BGL Company Info

Description

BioGaia AB (publ) develops, markets, and sells probiotic products with documented health benefits worldwide. It operates in Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula. The Adult Health segment provides gut health tablets and oral health lozenges products, as well as cultures, which are used as an ingredient in a dairy product. The Other segment provides animal health products. The company offers its products in the areas of baby and child care, including infantile colic, constipation, regurgitation, functional abdominal pain, and diarrhoea; gut health comprising diarrhoea and constipation; gastrointestinal health consisting of Helicobacter pylori–the gastric ulcer bacterium; and oral health, including gingivitis and periodontitis, caries, and halitosis. The company offers its products under the brand name of BioGaia through drug stores and pharmacies. BioGaia AB (publ) was founded in 1990 and is headquartered in Stockholm, Sweden.

Details
Name: BioGaia AB
BGL
Exchange: DB
Founded: 1990
SEK760,781,379
17,336,462
Website: http://www.biogaia.com
Address: BioGaia AB
Kungsbroplan 3,
Stockholm,
Stockholm County, 112 27,
Sweden
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OM BIOG B Class B Shares OMX Nordic Exchange Stockholm SE SEK 29. May 1998
OTCPK BGAI.F Class B Shares Pink Sheets LLC US USD 29. May 1998
DB BGL Class B Shares Deutsche Boerse AG DE EUR 29. May 1998
LSE 0GTN Class B Shares London Stock Exchange GB SEK 29. May 1998
BATS-CHIXE BIOGBs Class B Shares BATS 'Chi-X Europe' GB SEK 29. May 1998
OTCPK BIOG.Y UNSPONSORED ADR Pink Sheets LLC US USD 04. Apr 2013
Number of employees
Current staff
Staff numbers
143
BioGaia employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/23 20:47
End of day share price update: 2019/04/23 00:00
Last estimates confirmation: 2019/04/15
Last earnings filing: 2019/03/25
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.